Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Glaukos Announces Participation in Upcoming Investor Conferences


Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:

A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.


These press releases may also interest you

at 02:03
Barrington James Announces Strategic Acquisition of S3 Science Recruitment
Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the...

at 02:00
Philips appoints Ling Liu as Chief Region Leader of Philips Greater China
July 3, 2024 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of...

at 01:39
Hansa Biopharma to host Q2 2024 interim results conference call
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...

at 01:05
BenevolentAI: Leadership Team Change
Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team...

at 00:15
/C O R R E C T I O N -- Wormington & Bollinger/
In the news release, AbbVie, Inc.'s Zymaxid tm Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death, issued 02-Jul-2024 by Wormington & Bollinger over PRWeb, the source of the release should be "Wormington & Bollinger"...

at 00:00
Your Doctor Has A Plan For Treating Cancer; So Does God
Author David W. Treaster shares a Christian-based plan that can supplement a cancer patient's medical treatment plan in God Power Cancer Healing Plan: Spiritual Component ($15.99, paperback, 9781662899942; $7.99, e-book, 9781662899959). As long as...

More news about Health...


News published on and distributed by: